Insmed (NASDAQ:INSM) Research Coverage Started at HC Wainwright

by · The Markets Daily

HC Wainwright began coverage on shares of Insmed (NASDAQ:INSM – Free Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $220.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.81) EPS, FY2027 earnings at $1.13 EPS, FY2028 earnings at $3.15 EPS, FY2029 earnings at $5.25 EPS and FY2030 earnings at $10.77 EPS.

INSM has been the topic of several other reports. Bank of America reiterated a “buy” rating and issued a $207.00 price objective on shares of Insmed in a research report on Monday, October 12th. The Goldman Sachs Group assumed coverage on Insmed in a research report on Thursday, September 24th. They issued a “buy” rating and a $188.00 price objective for the company. UBS Group reissued a “buy” rating on shares of Insmed in a research note on Thursday, October 8th. Mizuho set a $154.00 price objective on Insmed in a research report on Thursday, October 29th. Finally, Evercore reiterated an “outperform” rating and set a $170.00 price target on shares of Insmed in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.52.

View Our Latest Analysis on Insmed

Insmed Trading Up 5.2%

INSM stock opened at $114.40 on Wednesday. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a market cap of $25.10 billion, a P/E ratio of -40.57 and a beta of 0.83. The business has a fifty day moving average of $111.21 and a 200-day moving average of $124.36. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77.

Insmed (NASDAQ:INSM – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The company had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. During the same period last year, the firm posted ($1.75) EPS. The company’s revenue was up 268.4% on a year-over-year basis. As a group, equities research analysts expect that Insmed will post -1.86 EPS for the current year.

Insider Activity

In other news, Director David R. Brennan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This trade represents a 70.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of INSM. Pictet Asset Management Holding SA boosted its position in shares of Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock valued at $200,845,000 after purchasing an additional 537,188 shares in the last quarter. Sei Investments Co. increased its position in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after buying an additional 505,624 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Insmed in the 2nd quarter worth $139,966,000. Assenagon Asset Management S.A. raised its position in shares of Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after purchasing an additional 1,048,518 shares during the period. Finally, NWI Management LP increased its stake in Insmed by 2.6% in the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after acquiring an additional 25,540 shares during the last quarter.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Recommended Stories